On January 13, 2025, significant news emerged from the biotechnology sector as Synthego announced a new licensing agreement.

The agreement allows AstraZeneca access to Synthego's CRISPR gene editing enzymes, marking a strategic collaboration in genome engineering.

This development marks Synthego's second licensing agreement within the past year, underscoring its expanding capabilities in gene editing technology.

While the specifics of the agreement's terms were not disclosed, it is expected to enhance Synthego's offerings in the gene editing field.